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ABSTRACT 
With more than 8% of people in the United States diagnosed with type 2 diabetes, it is 
imperative to develop treatments that improve glycemic control (1). Previously, we reported that 
dietary safflower oil (8 g qd) significantly decreased trunk adipose mass, increased adiponectin 
levels, and decreased HbA1c levels in post-menopausal, obese women with type 2 diabetes 
mellitus (T2DM) (2). However, the specific components of safflower oil that contributed to 
altering adipose mass distribution and improving glycemic control are not known. Safflower oil 
(SAF) contains several compounds (e.g., tocopherols, tocotrienols, and linoleic acid) that may 
improve insulin sensitivity. The objectives of this study were to determine if supplementation 
with SAF (8 g qd for 16 weeks) increases alpha tocopherol or gamma tocopherol levels in post-
menopausal women with T2DM and to measure the relationship of serum tocopherols or linoleic 
acid with the insulin sensitizing cytokine, adiponectin, HbA1c, and trunk adipose. Tocopherols 
were extracted from frozen serum samples via solid phase extraction and analyzed using high 
performance liquid chromatography (HPLC) for gamma and alpha tocopherol concentrations at 
the baseline and the endpoints of the (SAF) supplementation. While not all of the subjects 
exhibited increased tocopherol, the subjects who showed an increase in tocopherol concentration 
had a significant increase in plasma adiponectin and a significant decrease in trunk adipose mass 
and HbA1c. Overall, the data suggest that alpha and gamma tocopherol may contribute to the 
improvements in markers of glycemia in obese post-menopausal women with T2DM. 
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Confounding factors that may have contributed to variability within our observations are related 
to the nature of this study being a secondary analysis derived from a primary study (2).   The 
number of observations (n) was limited due to the primary objective (2).  In addition, these 
considerations include possible exposure of samples to more than one freeze-thaw cycle, 
unregulated exposure to light, and duration of storage in -80C freezer. This study provides 
evidence that in addition to linoleic acid, tocopherols found in dietary SAF may contribute to 
improved glycemic control in women with (T2DM). 
 
INTRODUCTION 
Currently, it is estimated that more than 25.8 million (or 8.3%) of people in the United 
States alone have been diagnosed with diabetes (1).  Due to the rising trend in obesity, the 
prevalence of type 2 diabetes mellitus (T2DM) continues to increase at a staggering rate.  The 
primary factor in the development of T2DM is centralized (android pattern) obesity coupled with 
substantial weight gain leading to impaired glucose tolerance and fasting glucose ultimately 
resulting in insulin resistance.  While healthy eating, moderate exercise, and weight loss 
significantly improve glycemic control, weight loss is not always a viable or realistic option for 
many obese patients with diabetes.  However, current research continues to reveal more effective 
and less costly drug therapy and dietary supplement options to curb T2DM and provide stable 
glycemic control.   
 In particular, safflower oil, a cost-effective and widely available natural dietary 
supplement, has been the subject of several T2DM studies for improving insulin sensitivity and 
glycemic control.  However, the specific components of safflower oil that contributed to altering 
adipose mass distribution and improving glycemic control have yet to be characterized. 
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Safflower oil is a colorless and flavorless dietary oil that is rich in the omega-6 (n-6) fatty acid, 
linoleic acid, and vitamin E.  The polyunsaturated fatty acid (PUFA) n-6 linoleic acid (18:2n6) 
found in safflower oil promotes heart health and was recently found to improve body weight and 
body composition (3).  Vitamin E refers to a group of compounds that include tocopherols and 
tocotrienols that are known antioxidants yet their effects on weight loss and adipose distribution 
have yet to be fully understood.  In a previous study (The Women’s Diabetes Study), safflower 
oil decreased trunk adipose mass, lowered fasting glucose, and increased adiponectin levels in 
postmenopausal women with T2DM (2).   
The results of the study suggested that the tocopherols and/or linoleic acid provided by 
the safflower oil may mimic the mechanism of a class of prevalent diabetes drugs, 
thiazolidinediones (TZDs), though the implications of this hypothesis are still unclear.  TZDs act 
by binding peroxisome proliferator-activated receptor γ (PPARγ) (4).  Binding to the PPARγ 
induces secretion of adipokines (particularly adiponectin) by the adipocytes resulting in 
significant increases in insulin sensitivity (Figure 1).   
 
 
 
 
 
 
 
FIGURE 1:  Proposed Mechanism of Tocopherols and/or Linoleic Acid 
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Unfortunately, TZDs have recently been scrutinized for possible weight gain, and more 
importantly, potential life-threatening cardiac and liver complications (5).  The problems with 
synthetic pharmaceutical TZDs have been attributed to their extremely high affinity for PPAR γ 
and/or the slow rate of metabolism.  In contrast, naturally occurring ligands for PPAR γ such as 
fatty acids and eicosanoids bind and activate PPAR γ with lower affinity and have more rapid 
turnover through metabolism; both advantages of naturally occurring ligands then offer a lower 
likelihood of toxicity.  Tocopherols were recently shown to promote PPAR γ-mediated gene 
expression and phenotypic outcomes in experimental animals and cell culture (6).  The results of 
the Women’s Diabetes Study showing improved glycemic control with SAF oil supplementation 
coupled with previous studies demonstrating the ability of safflower oil to increase adiponectin 
levels and improve glycemic control may be attributed to the tocopherol components promoting 
a PPARγ-mediated mechanism similar to TZDs but without the potency and the side effects of 
the synthetic drug (2).   
This study is secondary analysis of the data and frozen serum samples from the Women’s 
Diabetes Study with following two-pronged objective:  1) To determine the extent that 
supplementation with safflower oil increases serum tocopherol levels in post-menopausal women 
with T2DM; 2) To quantify the strength of the relationship between plasma tocopherol levels and 
improved glycemia (reduced fasting glucose) via a PPARγ binding mechanism. 
 
MATERIALS AND METHODS 
WDS Overview 
The study was a 36-wk randomized, double blind, cross-over design that was approved 
by the Ohio State University Institutional Review Board and CRC Advisory Board. Fifty-five 
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postmenopausal women with T2DM received SAF or CLA (8 g qd) during two 16-week diet 
periods separated by a 4-week washout period (Figure 2).   
 
 
 
FIGURE 2:  Experimental design of the Women’s Diabetes Study 
Dual-energy X-ray absorptiometry (DXA) was used to determine body composition.  Fasting 
blood samples were collected from subjects every 16 weeks and plasma samples were analyzed 
for glucose, insulin, leptin, and adiponectin by the General CRC Laboratory Core.  Serum 
linoleic acid was analyzed by gas chromatography in the Belury Laboratory and described 
previously (7). 
Study Design 
Frozen serum samples from the primary study were selected for secondary analysis.  
Only samples that represented the baseline and endpoints of the safflower supplementation were 
analyzed for serum α-tocopherol and ϒ-tocopherol concentrations. Serum tocopherol 
concentrations as well as previously reported linoleic acid levels were then compared to HbA1c , 
adiponectin, and trunk adipose using least squares linear regression and matched paired t-test. 
Tocopherol Standard Preparation 
Stock solutions of α-tocopherol and ϒ-tocopherol (Supelco) were prepared in chloroform 
at 50 and 12.5 mg/mL respectively. A stock solution of Rac-tocol (Matreya, LLC) was prepared 
in methanol at 500uM. Subsequent dilutions were performed into methanol to produce mixed 
tocopherol standards at 50uM and 500uM, and a Rac-tocol internal spike of 50uM. These 
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standards were used to make the daily calibration standards for quantification ranging from 1 to 
100uM with Rac-tocol at 25uM. 
Sample Preparation 
Frozen serum samples were thawed on ice at room temperature and an internal standard 
(50 uL, 50 uM tocol) was added with 250uL of serum deproteinized by cooled ethanol (650 uL, 
8 min, 4ºC).  After centrifugation (2000 xg, 15 min, 4ºC), the supernatant was separated and 
acidified to pH 3 (10 uL, 1M, HCl).  Prior to solid phase extraction (SPE), the SPE column was 
conditioned with 3 mL of methanol, distilled water, and hydrochloric acid (1M).  The serum was 
extracted with ethyl acetate (3 mL), dried by nitrogen steam, and re-constituted with methanol 
(100 uL) in preparation for analysis (8).   
Tocopherol HPLC Method 
Chromatography was performed on a Shimadzu HPLC system (Columbia, MD) with 
detection by UV absorption at 295 nm.  Separation was achieved using an isocratic elution on a 
Chromolith Performance RP-18e, 100x4.6mm monolithic column (Merck).  The mobile phase 
was acetonitrile:  1% ammonium acetate in water, pH7 at a ratio of (95:5) and a flow rate of 
1.5mL/min for 7 minutes.  The column was then flushed at a ratio of acetonitrile: 1% ammonium 
acetate (98:2) with an increased flow rate of 3.2 mL/min for 4 minutes then was allowed to re-
equilibrate for 2 minutes.  A column heater was used to maintain ambient temperature at 25ºC.  
The injection volume was 20 uL (8).   
Statistical Analysis 
All statistical analyses were done using SPSS Software Version 19 
Analysis of Variance:  Comparisons between baseline and endpoint concentrations of α-
tocopherol, ϒ-tocopherol, and linoleic acid were analyzed using one-way ANOVA with p<0.10 
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considered significantly different.  Bonferroni method was used to adjust for multiple 
comparisons. 
Least Squares Linear Regression:  Serum concentrations of α-tocopherol, ϒ-tocopherol, and 
linoleic acid were analyzed by multiple least squares linear regression models with the change in 
α-tocopherol, ϒ-tocopherol, and linoleic acid as the independent variable and the change in 
adiponectin, HbA1c, and trunk adipose as the dependent variable 
Matched Paired T-test:  A matched paired t-test was also conducted between the subjects who 
had increases in ϒ-tocopherol, α-tocopherol, and linoleic acid from the baseline to the endpoint 
of SAF supplementation and the aforementioned dependent variables.  Data is presented as mean 
difference ± standard deviation (SD) with p<0.10 considered significantly different.  
 
RESULTS  
 Matched frozen serum samples were found for 29 of the 40 women who completed the 
safflower supplementation.  The data between diet period 1 (Weeks 0-16) and diet period 2 
(Weeks 20-36) for the safflower supplementation showed no significant difference.  Also, no 
differences were observed for age, ethnicity, BMI, duration of diabetes, and HbA1c at baseline of 
the diet groups.  Therefore, these data were overlapped to increase power of the statistical 
analyses.   
Tocopherol Analysis 
Serum concentrations of α-tocopherol and ϒ-tocopherol were analyzed via HPLC from 
the baseline and endpoints of safflower oil supplementation.  There was no significant increase 
in either α-tocopherol or ϒ-tocopherol during either 16-week diet period (p= 0.67).   
Linoleic Acid Analysis 
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Serum linoleic acid was previously analyzed by gas chromatography although the data 
had yet to be statistically analyzed.  A significant increase in linoleic acid was observed over the 
course of the SAF supplementation (p=0.10) (Figure 3). 
 
Descriptive Statistics 95% Confidence Interval 
p-value 
  Mean 
Std. 
Deviation 
n 
Lower 
Bound 
Upper 
Bound 
Baseline 
(Week 0) 
25.19 4.83 15 22.52 27.87 0.10 
Endpoint 
(Week 16)  
27.30 3.55 15 25.33 29.27   
 
FIGURE 3:  Change in Linoleic Acid Level from Baseline to Endpoint of SAF Supplementation.   
Linoleic acid is expressed as the % of total identified fatty acids. 
Anthropometric Variables 
The previous study reported no effect on total adipose mass, but a significantly reduced 
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change in α-tocopherol, ϒ-tocopherol, or linoleic acid and change trunk adipose mass from 
baseline to endpoint.  A matched paired t-test was performed in which only subjects who had an 
increase in α-tocopherol, ϒ-tocopherol, and linoleic acid (respectively) were compared to trunk 
adipose mass.  This analysis also showed no difference between the baseline and endpoint of 
SAF supplementation. 
Biochemical Measurements 
 Changes between α-tocopherol, ϒ-tocopherol, or linoleic acid and adiponectin or HbA1c 
were analyzed by least squares linear regression models (Table 1).  There was, however, a 
significant correlation between change in α-tocopherol and change in HbA1c (p=0.02) (Figure 4).   
Linear Regression Summary 
Dependent Variable Independent Variable Linear Regression – R2 Significance (p-value) 
ADIPONECTIN (ug/mL) ϒ-TOCOPHEROL (uM) 0.02 0.56 
HbA1c (%) ϒ-TOCOPHEROL (uM) 0.02 0.52 
TRUNKADIPOSE (g) ϒ-TOCOPHEROL (uM) 0.00 0.80 
ADIPONECTIN (ug/mL) α-TOCOPHEROL (uM) 0.02 0.53 
HbA1c (%) α-TOCOPHEROL (uM) 0.08 0.02* 
TRUNKADIPOSE (g) α-TOCOPHEROL (uM) 0.02 0.49 
ADIPONECTIN (ug/mL) LINOLEIC ACID (%) 0.05 0.30 
HbA1c (%) LINOLEIC ACID (%) 0.01 0.60 
TRUNKADIPOSE (g) LINOLEIC ACID (%) 0.00 0.90 
 
TABLE 1:  Linear Regression Summary. 
The independent and dependent variables are expressed as the difference between baseline and 
endpoint of safflower supplementation.  Values for each measurement that have (*) are 
significantly different at p<0.10 
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FIGURE 4:  Change in α-tocopherol (uM) negatively correlated to change in HbA1c (%) 
(p=0.02) at the p=0.10 level 
 To analyze the correlation between subjects who had increases in α-tocopherol, ϒ-
tocopherol, and linoleic acid to adiponectin and HbA1c, only subjects who had increases in α-
tocopherol, ϒ-tocopherol, and linoleic acid were included in a matched paired t-test taking the 
difference in means from baseline to endpoint of SAF supplementation for adiponectin and 
HbA1c (Table 2).  α-tocopherol, ϒ-tocopherol, and linoleic acid had no statistically significant 
effects on adiponectin.  However, both α-tocopherol and ϒ-tocopherol showed p-values that 
were marginal to the p=0.10 level (p=0.12, p=0.12 respectively) (Figure 5, 6).  By contrast, there 
was a significant decrease in HbA1c when compared to α-tocopherol, ϒ-tocopherol, and linoleic 
acid (Figure 7, 8, 9).   
Change in α-tocopherol (uM) is Negatively Correlated to Change in HbA1c (%) 
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Match Paired T-Test Summary 
Dependent 
Variable 
Independent 
Variable 
n 
Mean/Std Dev  Mean/Std Dev  Mean 
Difference 
Significance 
(p-value) Endpoint Baseline 
ϒ-
TOCOPHEROL 
(uM) 
ADIPONECTIN 
(ug/mL) 
12 11.4 +/- 8.5 9.2 +/- 6.6 2.2 0.12 
HbA1c (%) 11 7.0 +/- 1.2 8.2 +/- 2.0 -1.2 0.08* 
TRUNK 
ADIPOSE (g) 
11 
21788.2 +/- 
5356.0 
23418.9 +/- 
6382.4 
-1630.7 0.17 
α-
TOCOPHEROL 
(uM) 
ADIPONECTIN 
(ug/mL) 
13 10.0 +/- 7.0 7.8 +/- 3.1 2.2 0.12 
HbA1c (%) 13 7.2 +/- 1.2 8.3 +/- 1.9 -1.1 0.06* 
TRUNK 
ADIPOSE (g) 
11 
24229.5 +/- 
6021.3 
25099.5 +/- 
6088.8 
-870.0 0.45 
LINOLEIC 
ACID (%) 
ADIPONECTIN 
(ug/mL) 
15 7.9 +/- 6.1 6.4 +/- 3.3 1.5 0.17 
HbA1c (%) 16 7.0 +/- 0.9 7.5 +/- 1.2 -0.5 0.07* 
TRUNK 
ADIPOSE (g) 
14 
24305.0 +/- 
7531.5 
25012.5 +/- 
7359.2 
-707.5 0.48 
 
TABLE 2:  Match Paired T-Test Summary 
The independent and dependent variables are expressed as the difference between baseline and 
endpoint of safflower supplementation.  Endpoint (Wk 16) and Baseline (Wk 0) are represented 
as the mean difference ± standard deviation.  Values for each measurement that have (*) are 
significantly different at p<0.10 
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FIGURE 5:  Mean difference of adiponectin (ug/mL) from baseline to endpoint where change in 
α-tocopherol (uM) >0 (p = 0.12). 
 
 
 
 
 
 
 
 
FIGURE 6:  Mean difference of adiponectin (ug/mL) from baseline to endpoint where change in 
ϒ-tocopherol (uM) >0 (p=0.12). 
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FIGURE 7:  Mean difference in HbA1c (%) from baseline to endpoint where change in α-
tocopherol (uM) >0 (p=0.06). 
 
 
 
 
 
 
 
 
FIGURE 8:  Mean difference in HbA1c (%) from baseline to endpoint where change in α-
tocopherol (uM) >0 (p=0.08). 
 
 
 
 
 
 
 
 
FIGURE 9:  Mean difference in HbA1c (%) from baseline to endpoint where change in linoleic 
acid (% of total fatty acids) >0 (p=0.07). 
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DISCUSSION 
 The results of this study suggest that alpha and gamma tocopherol may contribute to the 
improvements in markers of glycemia (particularly plasma glucose as measured by HbA1c) in 
postmenopausal women with T2DM.  While the results were inconclusive in regards to whether 
safflower oil increases serum concentrations of tocopherol, there were significant increases in the 
% of linoleic acid (of total fatty acids) from baseline to end point of SAF supplementation.  
 Although there was not a significant increase in α-tocopherol and ϒ-tocopherol 
throughout SAF supplementation, those subjects who did have an increase in α-tocopherol, ϒ-
tocopherol, as and linoleic acid showed improved HbA1c  and adiponectin expression indicating 
improved insulin sensitivity.  Adiponectin regulates glucose metabolism by increasing glucose 
uptake and decreasing gluconeogenesis resulting in decreased HbA1c (9).  Because adiponectin 
transcription is responsive to PPARγ ligands, the increase in adiponectin expression may be due 
to linoleic acid which is a weak ligand for PPARγ.  While it has not yet been determined if 
tocopherols are a direct ligand to PPARγ, some animal studies suggest that tocopherols facilitate 
activation of PPARγ via stimulation of 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), a known 
PPARγ  ligand (6).  15d-PGJ2 seems to enhance binding of PPARγ to the PPARγ response 
element (PPRE) in the promoter region of the adiponectin gene therefore facilitating adiponectin 
expression (10).  Furthermore, α-tocopherol, ϒ-tocopherol, and linoleic acid did not show any 
correlation to a decrease in trunk adipose tissue even after women who did not have increases in 
tocopherol and linoleic acid were removed from statistical analysis.   
In the Women’s Diabetes study, SAF supplementation resulted in a decrease in trunk 
adipose mass and an increase in lean tissue mass resulting in no change in total BMI.  This 
phenomenon could be due to the insulin sensitizing effects of PPARγ.  The proposed mechanism 
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for α-tocopherol, ϒ-tocopherol, and linoleic acid to improve insulin sensitivity is through PPARγ 
activation.  PPARγ is a receptor for a popular diabetes drug, thiazolidinediones (TZDs) which 
triggers adipocyte differentiation improving glucose uptake and therefore, insulin sensitivity 
(11).  However, animal studies and clinical trials have shown that TZDs result in moderate 
weight gain and edema, possibly due to an increase in fat cell number and a decrease in fat cell 
size (12).  TZDs, however, bind PPARγ with high affinity so it is likely that a weaker ligand 
would result in milder side effects (little or no overall weight gain).  Because linoleic acid and 
tocopherols in safflower oil may function via a PPARγ dependent mechanism, the evidence of no 
change in BMI throughout safflower supplementation is consistent with the findings of other 
PPARγ ligands, specifically TZDs.   
There were some limitations to this study, many of which were due to the nature of this 
study being a secondary analysis of a study whose primary objective was not specific to the 
components of safflower oil.  First, the number of observations (n) was limited because only 29 
of the 40 women who finished the safflower supplementation had matched samples that were 
viable for analysis.  Therefore, a small number of women who may naturally not respond to 
safflower supplementation or absorb tocopherol from safflower oil would have had a strong 
effect on the outcome of the study.  The limited number of observations also affected the power 
of the statistical analysis since the matched paired t-test has lower power than some other 
statistical measures.  Also, the 16-week cross over design may not have provided adequate time 
to show maximum results of the safflower supplementation.  In addition, some confounding 
variables contributing to the observed tocopherol concentrations include possible exposure of 
samples to multiple freeze-thaw cycles, light exposure, and duration of storage in -80C freezer. 
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Overall, this study shows that α-tocopherol, ϒ-tocopherol, and linoleic acid are likely 
candidates for the insulin-sensitizing effects of safflower oil.  Also, while the mechanisms of 
linoleic acid and tocopherols that contribute to insulin sensitivity have yet to be fully understood, 
findings from this study indicate that α-tocopherol, ϒ-tocopherol, and linoleic acid may function 
through a PPARγ- mediated process.  Future studies should focus on prolonging the duration of 
the intervention and determining whether tocopherols and/or linoleic acid are responsible for 
improved glucose metabolism.  A method to compare the effectiveness of tocopherol versus 
linoleic acid would be to supplement vitamin E or linoleic acid to two randomly assigned 
treatment groups of postmenopausal women with T2DM.  An intervention of this nature would 
be useful in not only determining to what extent tocopherols and/or linoleic acid contribute to 
glucose metabolism, but would also be beneficial in determining the mechanisms of tocopherols 
and/or linoleic acid.   
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